JNJ-7706621 JNJ7706621 is a chemical compound that acts as an inhibitor of Aurora kinase and Cdk. The substance is also known by its chemical name, 4-({4-[4-(dimethylamino)piperidin-1-yl]phenyl}amino)-6-{[4-(methylsulfonyl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-7-one, and has a molecular formula of C28H33N7O2S, with a formula weight of 535.67 grams per mole. Its CAS No. is 443797-96-4. The substance has shown potential as a chemotherapeutic agent for the treatment of cancer, and its development is ongoing.
Top ten keywords from Google:
Synonyms:
JNJ-7706621 JNJ7706621 also goes by the following names:
Health Benefits of This Product:
JNJ-7706621 JNJ7706621 is a chemotherapeutic agent that has shown potential in the treatment of cancer. The substance works by inhibiting Aurora kinase and Cdk, two enzymes that are critical in regulating cell division. Through this mechanism, the substance can prevent the growth and multiplication of cancer cells.
Potential Effects:
JNJ-7706621 JNJ7706621 has the potential to be an effective chemotherapeutic agent for the treatment of cancer. Studies have shown it to be a potent inhibitor of Aurora kinase and Cdk, both of which are essential for cell division. Inhibition of these enzymes can prevent the growth and proliferation of cancer cells. It has also shown potential in the treatment of various types of cancer, including prostate, ovarian, and breast cancer.
Product Mechanism:
JNJ-7706621 JNJ7706621 works by inhibiting Aurora kinase, a crucial enzyme in the regulation of cell division, thereby preventing cells from progressing through the cell cycle. The substance also inhibits Cdk, which is a protein kinase that aids in the initiation and progression of cell division. Inhibiting both enzymes prevents the growth and proliferation of cancer cells, making JNJ-7706621 JNJ7706621 a promising chemotherapeutic agent for the treatment of cancer.
Safety:
The safety of JNJ-7706621 JNJ7706621 is currently being evaluated in clinical trials. However, preclinical studies have shown it to be safe with minimal toxicity, with the substance being well-tolerated in animal models. Further studies are needed to determine the substance's safety in humans.
Side Effects:
As with any medication, JNJ-7706621 JNJ7706621 may have some potential side effects. In preclinical studies, the substance did not exhibit significant toxicity or adverse effects. However, some possible side effects may include gastrointestinal distress, fatigue, and myelosuppression.
Dosing Information:
The optimal dose of JNJ-7706621 JNJ7706621 for the treatment of cancer is not yet determined but is currently being investigated in clinical trials. The substance is typically administered orally, with dosages ranging from 50 to 300 mg per day. However, the dosages may vary depending on the type and severity of the cancer being treated.
Conclusion:
JNJ-7706621 JNJ7706621 is a promising chemotherapeutic agent that targets Aurora kinase and Cdk, two enzymes essential to regulating cell division. The substance has shown potential in the treatment of various types of cancer, including prostate, ovarian, and breast cancer. The substance has minimal toxicity and has exhibited a low incidence of adverse effects. However, the optimal dosage and safety of the substance in humans are still being evaluated. JNJ-7706621 JNJ7706621 has shown potential as a valuable tool in the fight against cancer and may provide new hope for cancer patients.
